Recent Updates in The Role of Immunotherapies in NSCLC: Translating Evidence to Clinical Practice : Episode 9
CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.
EP: 1.Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
EP: 2.The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP: 3.Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials
EP: 4.Optimizing the Role of Neoadjuvant Immunotherapy in Resectable NSCLC
EP: 5.Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The NEOCoast Trial
EP: 6.The Role of Adjuvant Immunotherapy in the Treatment of Resectable NSCLC
EP: 7.Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC
EP: 8.Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors
Now Viewing
EP: 9.CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC
EP: 10.KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC
EP: 11.EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC
EP: 12.POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC
EP: 13.Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy
EP: 14.The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC
EP: 15.The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC
EP: 16.A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations
EP: 17.The Exciting Future of NSCLC Treatment
EP: 18.Is There a Role for IO Therapy in NSCLC With Independent KRAS, STK11, or KEAP1 Mutations?
EP: 19.POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations
EP: 20.Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations
EP: 21.Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations
EP: 22.Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations
Related Videos
Related Content
